Abivax pares gain after denying AstraZeneca speculation

Abivax pares gain after denying AstraZeneca speculation
Momentum traders are flagging several health care stocks that may be overheated heading into the new quarter. As of Feb. 18, 2026, elevated RSI readings suggest recent gains could be vulnerable to pullbacks despite strong headlines. AstraZeneca has surged roughly 14% over the https://t.co/eVMOTmA1TE
AstraZeneca profit climbs on cancer and heart drug demand
Walmart joins Nasdaq 100 on January 20, replacing AstraZeneca
AstraZeneca hails major breakthroughs with breast-cancer drugs
AstraZeneca to become latest drugmaker to strike deal with Trump. Its stock is down but outperforming the market.
290.6BUSD
Jenis
Common Stock
Menukarkan
PINK
Kode mata uang
USD
Nama Mata Uang
US Dollar
Nama negara
USA
ISO Negara
US
ADALAH
GB0009895292
CUSIP
-
Sektor
Healthcare
Industri
Drug Manufacturers - General
Akhir Tahun Anggaran
December
tanggal IPO
-
Diperbarui Pada
-
Rasio PE
31.09
Rasio PEG
1.67
Nilai buku
29.59
Pembagian Dividen
3.13
Hasil Dividen
1.70%
Bagi Hasil
6.03
Target Harga Wall Street
104.00
Estimasi EPS Tahun Ini
4.56
Estimasi EPS Tahun Depan
5.06
Perkiraan EPS Kuartal Saat Ini
0
Estimasi EPS Kuartal Berikutnya
0
Kuartal Terbaru
-
Pendapatan TTM
58,126,999,552
TTM Laba Kotor
48,395,001,856
EBITDA
20,416,000,000
Margin Keuntungan
16.17%
Pengembalian Aset TTM
9.06%
Pengembalian Ekuitas TTM
21.67%
Pendapatan Per Saham TTM
37.501
Pertumbuhan Pendapatan Kuartalan YOY
12.00%
Eps TTM yang diencerkan
6.03
Pertumbuhan Pendapatan Kuartalan YOY
78.00%
tertinggal PE
31.09
Maju PE
19
Harga Jual TTM
4.9994
Buku Harga MRQ
6.1782
Pendapatan Nilai Perusahaan
5
EBITDA Nilai Perusahaan
17
400.00
3.27%356.82
2.03%50.08
1.48%155.25
0.55%242.30
0.44%212.23
0.23%955.46
0.20%146.63
-5.33%393.19
-1.70%122.68
-0.41%